Literature DB >> 33509286

Efficacy of a multivalent vaccine against Fasciola hepatica infection in sheep.

Rafael Zafra1, Leandro Buffoni2, Raúl Pérez-Caballero1, Verónica Molina-Hernández3, María T Ruiz-Campillo3, José Pérez3, Álvaro Martínez-Moreno1, Francisco J Martínez Moreno1.   

Abstract

In this work we report the protection found in a vaccination trial performed in sheep with two different vaccines composed each one by a cocktail of antigens (rCL1, rPrx, rHDM and rLAP) formulated in two different adjuvants (Montanide ISA 61 VG (G1) and Alhydrogel®(G2)). The parameters of protection tested were fluke burden, faecal egg count and evaluation of hepatic lesions. In vaccinated group 1 we found a significant decrease in fluke burden in comparison to both unimmunised and infected control group (37.2%; p = 0.002) and to vaccinated group 2 (Alhydrogel®) (27.08%; p = 0.016). The lower fluke burden found in G1 was accompanied by a decrease in egg output of 28.71% in comparison with the infected control group. Additionally, gross hepatic lesions found in vaccine 1 group showed a significant decrease (p = 0.03) in comparison with unimmunised-infected group. The serological study showed the highest level for both IgG1 and IgG2 in animals from group 1. All these data support the hypothesis of protection found in vaccine 1 group.

Entities:  

Keywords:  Fasciola hepatica; Protection; Sheep; Vaccine

Mesh:

Substances:

Year:  2021        PMID: 33509286      PMCID: PMC7841919          DOI: 10.1186/s13567-021-00895-0

Source DB:  PubMed          Journal:  Vet Res        ISSN: 0928-4249            Impact factor:   3.683


  51 in total

1.  Vaccination with cathepsin L proteinases and with leucine aminopeptidase induces high levels of protection against fascioliasis in sheep.

Authors:  L Piacenza; D Acosta; I Basmadjian; J P Dalton; C Carmona
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Lack of protective efficacy in buffaloes vaccinated with Fasciola gigantica leucine aminopeptidase and peroxiredoxin recombinant proteins.

Authors:  O K Raina; Gaurav Nagar; Anju Varghese; G Prajitha; Asha Alex; B R Maharana; P Joshi
Journal:  Acta Trop       Date:  2011-03-03       Impact factor: 3.112

3.  Functional expression of Fasciola hepatica cathepsin L1 in Saccharomyces cerevisiae.

Authors:  L Roche; A J Dowd; J Tort; S McGonigle; A MacSweeney; G P Curley; T Ryan; J P Dalton; A McSweeney
Journal:  Eur J Biochem       Date:  1997-04-15

4.  Protection of cattle against a natural infection of Fasciola hepatica by vaccination with recombinant cathepsin L1 (rFhCL1).

Authors:  O Golden; R J Flynn; C Read; M Sekiya; S M Donnelly; C Stack; J P Dalton; G Mulcahy
Journal:  Vaccine       Date:  2010-06-25       Impact factor: 3.641

Review 5.  Cathepsin L proteinases as vaccines against infection with Fasciola hepatica (liver fluke) in ruminants.

Authors:  G Mulcahy; J P Dalton
Journal:  Res Vet Sci       Date:  2001-02       Impact factor: 2.534

6.  Fasciola hepatica leucine aminopeptidase, a promising candidate for vaccination against ruminant fasciolosis.

Authors:  Daniel Acosta; Martín Cancela; Lucia Piacenza; Leda Roche; Carlos Carmona; José F Tort
Journal:  Mol Biochem Parasitol       Date:  2007-11-22       Impact factor: 1.759

Review 7.  Current Threat of Triclabendazole Resistance in Fasciola hepatica.

Authors:  Jane M Kelley; Timothy P Elliott; Travis Beddoe; Glenn Anderson; Philip Skuce; Terry W Spithill
Journal:  Trends Parasitol       Date:  2016-04-02

8.  Comparative dynamics of peritoneal cell immunophenotypes in sheep during the early and late stages of the infection with Fasciola hepatica by flow cytometric analysis.

Authors:  Raúl Pérez-Caballero; F Javier Martínez-Moreno; Rafael Zafra; Verónica Molina-Hernández; Isabel L Pacheco; M Teresa Ruiz-Campillo; Alejandro Escamilla; José Pérez; Álvaro Martínez-Moreno; Leandro Buffoni
Journal:  Parasit Vectors       Date:  2018-12-14       Impact factor: 3.876

9.  Biochemical characterisation of the recombinant peroxiredoxin (FhePrx) of the liver fluke, Fasciola hepatica.

Authors:  Mary Sekiya; Grace Mulcahy; Jane A Irwin; Colin M Stack; Sheila M Donnelly; Weibo Xu; Peter Collins; John P Dalton
Journal:  FEBS Lett       Date:  2006-08-22       Impact factor: 4.124

10.  Identification of protective peptides of Fasciola hepatica-derived cathepsin L1 (FhCL1) in vaccinated sheep by a linear B-cell epitope mapping approach.

Authors:  Leandro Buffoni; Laura Garza-Cuartero; Raúl Pérez-Caballero; Rafael Zafra; F Javier Martínez-Moreno; Verónica Molina-Hernández; José Pérez; Álvaro Martínez-Moreno; Grace Mulcahy
Journal:  Parasit Vectors       Date:  2020-07-31       Impact factor: 3.876

View more
  5 in total

Review 1.  Fasciolosis-An Increasing Challenge in the Sheep Industry.

Authors:  Snorre Stuen; Cecilie Ersdal
Journal:  Animals (Basel)       Date:  2022-06-08       Impact factor: 3.231

Review 2.  Chronic Wasting Due to Liver and Rumen Flukes in Sheep.

Authors:  Alexandra Kahl; Georg von Samson-Himmelstjerna; Jürgen Krücken; Martin Ganter
Journal:  Animals (Basel)       Date:  2021-02-19       Impact factor: 2.752

Review 3.  Promising Technologies in the Field of Helminth Vaccines.

Authors:  Dilhan J Perera; Momar Ndao
Journal:  Front Immunol       Date:  2021-08-19       Impact factor: 7.561

4.  Timing of Transcriptomic Peripheral Blood Mononuclear Cell Responses of Sheep to Fasciola hepatica Infection Differs From Those of Cattle, Reflecting Different Disease Phenotypes.

Authors:  Dagmara A Niedziela; Amalia Naranjo-Lucena; Verónica Molina-Hernández; John A Browne; Álvaro Martínez-Moreno; José Pérez; David E MacHugh; Grace Mulcahy
Journal:  Front Immunol       Date:  2021-09-20       Impact factor: 7.561

5.  Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth Fasciola hepatica.

Authors:  Krystyna Cwiklinski; Orla Drysdale; Jesús López Corrales; Yolanda Corripio-Miyar; Carolina De Marco Verissimo; Heather Jewhurst; David Smith; Richard Lalor; Tom N McNeilly; John P Dalton
Journal:  Vaccines (Basel)       Date:  2022-01-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.